{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Explosion of a New Designer Drug, Flakka: Implications for Practice

Activity Steps

Purpose of Activity

To provide information on the new designer drug, flakka.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Identify the pharmacokinetics and the physiological and psychological effects of flakka use.
  2. Examine the treatment of flakka users and the implications for healthcare providers.
Price: $12.95


  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Test Code: JAN1018
Published: Oct/Dec 2018
Expires: 12/4/2020
Required Passing Score: 13/18 (72%)
Authors: Deborah Salani, DNP, PMHNP-BC, APRN, NE-BC; Laura D. Albuja, DNP, APRN, FNP-C; Martin M. Zdanowicz, PhD, MEd, MA
Categories: Addiction , Emergency care